Hypothesis: Patients with Gestational Diabetes Mellitus (GDM) have a high risk to develop complications during pregnancy, puerperium and in the newborn. At present there are not scientific evidences about the optimal distribution of meals in the medical nutrition therapy (MNT) and their relationship with glycemic control. Aim: To explore and compare ketonemia and glycemic profile in patients with GDM that follow a MNT distributed in 6 or 3 meals. Besides, we want to explore the differences between both treatments in glucose dynamics. Methods: The study design is a randomized, crossover and multicentric trial. A sample of 10 patients with GDM will be recruited in the Department of Endocrinology and Nutrition from both centres. In a randomized manner patients will follow the conventional treatment (a carbohydrate-controlled diet distributed in 6 meals: 3 main meals and 3 snacks) and the intervention treatment (a carbohydrate-controlled diet distributed in 3 meals: breakfast, lunch and dinner). They will be randomized to begin with one of the two treatments, and after two weeks they will be switched to the other treatment. Patients will wear a blinded continuous glucose monitoring device (iPro2-TM, Medtronic) during the entire study period. Inclusion criteria: * Women with GDM diagnosed in 24-28 weeks. * Age 18-40 years. * Pregnancy age of 28-32 weeks. * Caucasian. * Body mass index ≤ 35 Kg/m2. Exclusion criteria: * Unability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia. * A low adherence to MNT. * Problems with written and/or oral communication. * Presence of comorbidities other than obesity, hypertension and dyslipidemia. * Insulin-need criteria within 3 first days of the beginning of the study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL). Clinical and sociodemographic variables will be assessed. Dietary records and blood samples will be collected. Daily basal ketonuria and ketonemia before each meal will be assessed. Glycemic profile will be collected with a blind-sensor during the four weeks of the intervention study. Generalized linear model analysis will be performed. Statistical power will be 80% and significance level will be set at 0.05. Written informed consent will be collected from all participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
10
Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
Berta Soldevila
Badalona, Barcelona, Spain
Marta Hernández
Lleida, Spain
Preprandial ketonemia
Before the 3 main meals every day.
Time frame: 4 weeks (2 weeks with the conventional treatment and 2 weeks with the intervention treatment)
Glycemic profile below pregnancy target capillary blood glucose concentration
Self monitoring blood glucose levels: pre meals \< 90 mg/dL, 1 hour post meals \<140mg/dL
Time frame: 4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment)
Area under the curve of interstitial glucose levels
Blinded continuous glucose monitoring data, iPro2, Medtronic (r)): diurnal (from 7 am to 11 pm) and nocturnal (from 11pm to 7 am)
Time frame: Time Frame: 4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment)
Fetal Macrosomia
US assessed fetal weight, adjusted for national standardized charts
Time frame: Through study completion, 4 weeks
Newborn body weight adjusted for gestational age (national standardized charts)
Large for gestational age \> 90th centile, small for gestational age \< 10th centile
Time frame: At delivery
Newborn hypoglycemia
Serum glycemia \<40 mg/dL in the first 48 hours of life
Time frame: 48 hours from delivery
Postpartum glucose tolerance of the mother
Plasma glucose levels fasting and 120 minutes after a 75 g oral glucose load
Time frame: 6 weeks after delivery
Point-of-care glycated hemoglobin (HbA1c)
DCA Vantage Analyzer, Siemens ®
Time frame: Every 2 weeks from the date of randomization until the last visit of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.